Ginkgo Bioworks Holdings, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue (1) | $27,711 | $29,380 | $67,341 | $106,744 |
| Costs and operating expenses: | ||||
| Cost of other revenue | 1,806 | 4,625 | 6,623 | 14,095 |
| Research and development | 40,945 | 69,353 | 137,075 | 193,646 |
| General and administrative | 28,593 | 36,986 | 97,198 | 111,690 |
| Restructuring charges | — | 721 | — | 8,753 |
| Total operating expenses | 71,344 | 111,685 | 240,896 | 328,184 |
| Loss from operations | (43,633) | (82,305) | (173,555) | (221,440) |
| Other income (expense): | ||||
| Interest income, net | 3,060 | 5,742 | 9,888 | 17,906 |
| Loss on equity method investment | (2,008) | — | (6,681) | — |
| Gain (loss) on investments | (287) | 3,684 | 486 | (238) |
| Other income (expense), net | 1,613 | (474) | (4,725) | (6,280) |
| Total other income (expense) | 2,378 | 8,952 | (1,032) | 11,388 |
| Loss from continuing operations before income taxes | (41,255) | (73,353) | (174,587) | (210,052) |
| Income tax (benefit) expense | (271) | 1 | (223) | (194) |
| Net loss from continuing operations | $(40,984) | $(73,354) | $(174,364) | $(209,858) |
| Net income (loss) from discontinued operations, net of tax | — | (7,401) | 4,083 | (22,154) |
| Net loss | $(40,984) | $(80,755) | $(170,281) | $(232,012) |
| Net income (loss) per share: | ||||
| From continuing operations | $(0.64) | $(1.32) | $(2.82) | $(3.82) |
| From discontinued operations | — | (0.13) | 0.07 | (0.40) |
| Total net loss per share | $(0.64) | $(1.45) | $(2.75) | $(4.22) |
| Weighted average common shares outstanding: | 63,966,054 | 55,633,718 | 61,890,748 | 54,916,539 |
| Comprehensive loss: | ||||
| Net loss | (40,984) | (80,755) | (170,281) | (232,012) |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustment | (515) | 27 | (1,128) | 3,462 |
| Unrealized (loss) gain on available-for-sale securities | (320) | 316 | (608) | 340 |
| Total other comprehensive (loss) income | (835) | 343 | (1,736) | 3,802 |
| Comprehensive loss | $(41,819) | $(80,412) | $(172,017) | $(228,210) |
(1)Includes related party revenue ofzero for the three months ended September 30, 2026 and 2025, andzero and$8,518 for thenine months ended September 30, 2026 and 2025, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.